Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.
Autori:
Ballerini M, Lucchini E, Ravano E, Rosa J, Patti C, Arcari A, Cavallo F, Ballotta L, Loseto G, Evangelista A, Tabanelli V, Zaja F.
Fonte:
Annals of Hematology